Trials / Conditions / Recurrent Endometrial Clear Cell Adenocarcinoma
Recurrent Endometrial Clear Cell Adenocarcinoma
5 registered clinical trials studyying Recurrent Endometrial Clear Cell Adenocarcinoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovaria NCT05950464 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer NCT04906382 | Floor Backes, MD | EARLY_Phase 1 |
| Active Not Recruiting | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel a NCT03914612 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer NCT03120624 | Mayo Clinic | Phase 1 |
| Unknown | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer NCT00492778 | GOG Foundation | Phase 2 |